http://orcid.org/0000-0003-1930-9625
REFERENCES
- He, J., X. Zhang, Y. Wei, et al. 2016. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nature Medicine 22(9): 991–993.
- Humrich, J. Y., C. von Spee-Mayer, E. Siegert, et al. 2015. Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE. Annals of the Rheumatic Diseases 74(4): 791–792.
- Humrich, J. Y., C. von Spee-Mayer, E. Siegert, et al. 2019. Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: An investigator-initiated, single-centre phase 1 and 2a clinical trial. The Lancet Rheumatology 1(1): e44–e54.
- Johnson, L. M., D. M. Duenas, and B. S. Wilfond. 2020. Ethical drug development for rare childhood diseases: When there are limited but promising data in adults, how to choose between safety or efficacy studies? The American Journal of Bioethics 20(4): 102–103.
- Juul, S. E., R. J. McPherson, L. A. Bauer, K. J. Ledbetter, C. A. Gleason, and D. E. Mayock. 2008. A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: Pharmacokinetics and safety. Pediatrics 122(2):383–391.
- Shah, S., A. Whittle, B. Wilfond, G. Gensler, and D. Wendler. 2004. How do institutional review boards apply the federal risk and benefit standards for pediatric research. The Journal of American Medical Association 291(4): 476–482.
- U.S. Congress. 2002. Best Pharmaceuticals for Children Act. 107th Congress, S. 1789. Available at: https://www.congress.gov/107/plaws/publ109/PLAW-107publ109.pdf (accessed February 26, 2020).
- U.S. Congress. 2003. Pediatric Research Equity Act of 2003. 108th Congress, S. 650 Available at: https://www.congress.gov/108/plaws/publ155/PLAW-108publ155.pdf (accessed February 26, 2020).
- U.S. Food and Drug Administration (FDA). 2018. The drug development process: Step 3: Clinical research. https://www.fda.gov/patients/drug-development-process/step-3-clinical-research. (accessed December 31, 2019).
- von Spee-Mayer, C., E. Siegert, D. Abdirama, et al. 2016. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases 75 (7): 1407–1415.